In a significant advancement for influenza vaccination, the U.S. Food and Drug Administration (FDA) has granted approval for the first mRNA-based flu vaccine developed by Moderna. This decision comes after a thorough review process that included initial pushback from regulatory officials. The vaccine, named mFLUSIVA, is expected to provide enhanced protection against seasonal flu, particularly for older adults. The approval marks a breakthrough in vaccine technology, following the success of mRNA vaccines in combating COVID-19.